Extended Data Figure 2. Pyrexia and biomarkers over time.

a, The graph on the left shows patients who developed pyrexia during the first cycle of MPDL3280A treatment by day. The graph on the right shows patients who developed pyrexia during all cycles of treatment with MPDL3280A. The percentage of patients with pyrexia and the number of patients available for analysis at each time point is indicated below the graph. b, Changes in CD8¹HLA-DR¹Ki-67¹ cells over the first 5 cycles of treatment with MPDL3280A. The y axis represents the log₂ fold-change versus C1D1 pre-dose level. Error bars are standard error of the mean. Samples from 164 patients were examined at cycle (C) 1 day (D) 1 (C1D1) and 145 patients at C2D1. The P value for the difference in fold change between C2D1 versus C1D1 was, 0.00001. c, Changes in IFN-c, ITAC, IL-18 and IL-6 levels shown over the first seven 21-day cycles of treatment with MPDL3280A. To measure fold changes in IFN-c and IL-6 levels, 112 and 109 patient samples were examined for C1D1 and C2D1, respectively. To measure fold changes in IL-18, 260 and 253 patient samples were examined for C1D1 and C2D1, respectively; to measure ITAC, 262 and 256 patient samples were examined for C1D1 and C2D1, respectively. The adjusted P values comparing C2D1 versus C1D1 were 0.94 for IFN-c, 1 for IL-6, 0.00001 for IL-18 and, 0.00001 for ITAC. Error bars are standard error of the mean.